L T H Godding, A Dekker-Klaassen, J H Volders, M van Hezewijk, E J M Siemerink, D van Uden, J Veltman, A H Eijkelboom, S Siesling
{"title":"The Added Value of Physical Examination for Breast Cancer Recurrence Detection in Women: A Systematic Review.","authors":"L T H Godding, A Dekker-Klaassen, J H Volders, M van Hezewijk, E J M Siemerink, D van Uden, J Veltman, A H Eijkelboom, S Siesling","doi":"10.1016/j.clbc.2024.12.014","DOIUrl":null,"url":null,"abstract":"<p><p>As the number of curatively treated breast cancer patients grows and the burden on healthcare increases, effective use of methods to detect recurrences is becoming more important. This systematic review aims to examine the added value of physical examination (PE) in addition to mammography for breast cancer recurrence detection. PubMed, Web of Science, and Scopus were searched. Observational studies including women with a primary diagnosis of invasive or in situ breast cancer without metastases, which reported method of detection for locoregional recurrences (LRRs), and in which PE was defined as examination by a healthcare provider in an asymptomatic patient were included. Quality was assessed using the ROBINS-1 tool. Nine studies were included with data on 14,406 women, 613 LRRs and 349 secondary primary breast cancers. Of the total LRRs, 46.3% were detected by patients, 23.3% by mammography, and 14.8% by PE. PE detected 11% of the LRRs in patients who had breast conserving surgery and 28% of the LRRs in mastectomy patients. PE detected 7.1% of the contralateral breast cancers and 18.8% of ipsilateral lymph node recurrences, compared to 43.9% and 29.2% by mammography. PE detected a LRR in 0.6% of the patients (91/14,406) and mammography in 1.5% of the patients (143/9614). For detection of breast cancer recurrences, PE is of limited added value alongside mammography and self-detection, although it seems more beneficial for mastectomy patients. Further research is required to determine the effectiveness of the most efficient interval for PE across different patient groups.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clbc.2024.12.014","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
As the number of curatively treated breast cancer patients grows and the burden on healthcare increases, effective use of methods to detect recurrences is becoming more important. This systematic review aims to examine the added value of physical examination (PE) in addition to mammography for breast cancer recurrence detection. PubMed, Web of Science, and Scopus were searched. Observational studies including women with a primary diagnosis of invasive or in situ breast cancer without metastases, which reported method of detection for locoregional recurrences (LRRs), and in which PE was defined as examination by a healthcare provider in an asymptomatic patient were included. Quality was assessed using the ROBINS-1 tool. Nine studies were included with data on 14,406 women, 613 LRRs and 349 secondary primary breast cancers. Of the total LRRs, 46.3% were detected by patients, 23.3% by mammography, and 14.8% by PE. PE detected 11% of the LRRs in patients who had breast conserving surgery and 28% of the LRRs in mastectomy patients. PE detected 7.1% of the contralateral breast cancers and 18.8% of ipsilateral lymph node recurrences, compared to 43.9% and 29.2% by mammography. PE detected a LRR in 0.6% of the patients (91/14,406) and mammography in 1.5% of the patients (143/9614). For detection of breast cancer recurrences, PE is of limited added value alongside mammography and self-detection, although it seems more beneficial for mastectomy patients. Further research is required to determine the effectiveness of the most efficient interval for PE across different patient groups.
随着治愈乳腺癌患者人数的增加和医疗保健负担的增加,有效使用检测复发的方法变得越来越重要。本系统综述旨在探讨乳腺x光检查(PE)对乳腺癌复发检测的附加价值。检索了PubMed、Web of Science和Scopus。观察性研究包括原发诊断为浸润性或原位乳腺癌但无转移的女性,这些研究报告了局部复发(LRRs)的检测方法,其中PE被定义为由医疗保健提供者在无症状患者中进行的检查。使用ROBINS-1工具评估质量。9项研究纳入了14406名女性、613名低死亡率患者和349名继发性原发性乳腺癌患者的数据。在总lrr中,患者检出46.3%,乳房x光检查23.3%,PE检查14.8%。PE在保乳手术患者中检测到11%的LRRs,在乳房切除术患者中检测到28%的LRRs。PE检查对侧乳腺癌的检出率为7.1%,同侧淋巴结复发的检出率为18.8%,而x光检查的检出率为43.9%,同侧淋巴结复发的检出率为29.2%。PE检出LRR的患者为0.6%(91/ 14406),乳房x光检查检出LRR的患者为1.5%(143/9614)。对于乳腺癌复发的检测,PE与乳房x线摄影和自我检测的附加价值有限,尽管PE似乎对乳房切除术患者更有益。需要进一步的研究来确定在不同患者群体中最有效的PE间隔的有效性。
期刊介绍:
Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.